<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622865</url>
  </required_header>
  <id_info>
    <org_study_id>AB20001</org_study_id>
    <secondary_id>2020-001635-27</secondary_id>
    <nct_id>NCT04622865</nct_id>
  </id_info>
  <brief_title>Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19</brief_title>
  <official_title>Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin&#xD;
      in adult hospitalized patients with moderate and severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) that is&#xD;
      associated with substantial morbidity and mortality. There is currently no vaccine to prevent&#xD;
      COVID-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19.&#xD;
&#xD;
      Many patients with moderate and severe COVID-19, develop a &quot;cytokine storm&quot; that leads to&#xD;
      severe pulmonary inflammation and various thrombotic events associated with acute respiratory&#xD;
      distress syndrome (ARDS) and potentially death. The combination of masitinib and isoquercetin&#xD;
      may prevent the development of these two complications. Masitinib is a potent blocker of mast&#xD;
      cells and macrophages that are contributors to the cytokine storm. Isoquercetin inhibits&#xD;
      disulfide isomerase (PDI), an enzyme directly involved in the formation of clots, and also&#xD;
      decreases D-Dimer, a predictor of COVID-19 thrombosis severity.&#xD;
&#xD;
      The primary objective of this study is to evaluate efficacy of the masitinib and isoquercetin&#xD;
      combination in moderate and severe COVID-19 patients. The primary endpoint is subject&#xD;
      clinical status at day 15, using a 7-point ordinal scale that is defined as follows: 1. Not&#xD;
      hospitalized, no limitations on activities; 2.Not hospitalized, limitation on activities; 3.&#xD;
      Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental&#xD;
      oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6.&#xD;
      Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical status of patients at day-15 using a 7-point ordinal scale</measure>
    <time_frame>15 days</time_frame>
    <description>Ordinal scale defined as follows: 1. Not hospitalized, no limitations on activities; 2.Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>SARS-CoV 2</condition>
  <condition>COVID-19</condition>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Masitinib plus Isoquercetin plus Best Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive oral masitinib dose of 3 mg/kg/day for 4 days then 4.5 mg/kg/day.&#xD;
The dose of isoquercetin will be 1 g/day by oral route. Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <description>Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.</description>
    <arm_group_label>Masitinib plus Isoquercetin plus Best Supportive Care</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoquercetin</intervention_name>
    <description>Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.</description>
    <arm_group_label>Masitinib plus Isoquercetin plus Best Supportive Care</arm_group_label>
    <other_name>quercetin-3-O-glucoside</other_name>
    <other_name>isotrifoliin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.</description>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_label>Masitinib plus Isoquercetin plus Best Supportive Care</arm_group_label>
    <other_name>BSC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has laboratory-confirmed SARS-CoV-2 infection&#xD;
&#xD;
          -  Hospitalized patients for the treatment of COVID pneumopathy&#xD;
&#xD;
          -  Patients not requiring ICU at admission with moderate and severe pneumopathy according&#xD;
             to the OMS Criteria of severity of COVID pneumopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Chanez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Diseases, Aix-Marseille University, Marseille, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Study Coordinator</last_name>
    <phone>+33(0)147200014</phone>
    <email>clinical@ab-science.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand: Site Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Nord, AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Orleans, Hopital de la Source</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey, CHU du Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

